AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 November press release. It is the first asset licensed by the British big ...
T cells are central to the body's defense ... anti-tumor immunity is an emerging area in cancer therapy, systemically inhibiting Tregs can cause severe autoimmune reactions. This challenge has ...
A University professor has found a new way to treat cancer using different cell compounds, like the NR0B2 protein.
Regenerative medicine has the potential to reshape how we treat diseases, offering new hope for patients requiring cell, ...
The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.
It highlights the strong commitment and rapid integration of our respective research teams as well as providing important early validation of our novel CAR-Treg cell therapy approach to autoimmune ...
While the human body’s immune system is generally able to defend against harmful germs, diseases like cancer are trickier to ...
Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no ...
Researchers collaborated on a novel, highly specific strategy to treat type 1 diabetes using a tagged beta cell transplant in ...